Copenhagen-based Coloplast posted profits of DKK 2.7 billion (roughly $490.6 million) on sales of DKK 11.64 billion (~$2.0 billion) for the 12 months ended Sept. 30, representing profit growth of 23.6% on sales growth of 5.6%.
Fourth-quarter profits were DKK 749 million (~$135.6 million) on sales of DKK 2.97 billion (~$537.5 million), for bottom-line growth of 23.2% on sales growth of 4.2%.
"I’m very pleased with our strong full-year financial results. We lifted both our sales growth and our EBIT margin to the upper end of our guidance range. With our healthy growth performance in all business areas and in all regions during the past financial year, we have consolidated our position as a global market leader," CEO Lars Rasmussen said in prepared remarks. "These are excellent results. We grew our business by 7% overall in a market that is growing by 4–5%. We’re beginning to see the results of the investments in growth we announced in 2012, and we expect this strong growth to continue into next year."
Coloplast said it expects revenue growth of roughly 7% for fiscal 2014.
COLO B shares are up 7.6% to DKK 350.10 since their close Oct. 30, the day before the earnings release.
The company also said it inked a distribution deal with Devon Medical International for Devon’s negative-pressure wound therapy products in the European Union, Brazil, China and "other markets."
"Our Wound Care business has grown for three straight quarters, and we’ve now completed the turnaround we initiated a few years back. The deal with Devon is a natural next step in achieving our ambition for sustained growth in this business area," Rasmussen said in a statement.